001     285050
005     20260304110135.0
024 7 _ |a 10.1038/s41593-025-02136-5
|2 doi
024 7 _ |a pmid:41398477
|2 pmid
024 7 _ |a pmc:PMC12880920
|2 pmc
024 7 _ |a 1097-6256
|2 ISSN
024 7 _ |a 1546-1726
|2 ISSN
037 _ _ |a DZNE-2026-00174
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Todorov-Völgyi, Katalin
|0 0009-0007-8073-9524
|b 0
245 _ _ |a The stroke risk gene Foxf2 maintains brain endothelial cell function via Tie2 signaling.
260 _ _ |a New York, NY
|c 2026
|b Nature America
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1772532144_20772
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cerebral small vessel disease (SVD) is a common chronic cerebrovascular disorder with poorly understood pathomechanisms. Genetic studies have identified FOXF2 as a major risk gene for both SVD and stroke. FOXF2 encodes a transcription factor primarily expressed in brain pericytes and endothelial cells (ECs); however, its mechanistic role in cerebrovascular disease remains unknown. Here we show that Foxf2 maintains EC function through Tie2 signaling. RNA and chromatin sequencing identified FOXF2 as a transcriptional activator of Tie2 and other endothelial lineage-specific genes. The deletion of EC-specific Foxf2 in adult mice resulted in blood-brain barrier leakage, which worsened after experimental stroke. Proteomic analyses of Foxf2-deficient mouse brain-derived and human-induced pluripotent stem cell-derived ECs that lack FOXF2 revealed a downregulation of multiple proteins involved in Tie2 signaling. Endothelial Foxf2 deficiency impaired functional hyperemia, reduced NO production and increased infarct size through disrupted Tie2 signaling, effects that were rescued by pharmacological activation of Tie2 with AKB-9778. Collectively, our results highlight the critical role of Foxf2-regulated Tie2 signaling in SVD and stroke, suggesting new avenues for therapeutic interventions.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Forkhead Transcription Factors
|2 NLM Chemicals
650 _ 7 |a Receptor, TIE-2
|0 EC 2.7.10.1
|2 NLM Chemicals
650 _ 7 |a Tek protein, mouse
|0 EC 2.7.10.1
|2 NLM Chemicals
650 _ 7 |a Foxf2 protein, mouse
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Forkhead Transcription Factors: genetics
|2 MeSH
650 _ 2 |a Forkhead Transcription Factors: metabolism
|2 MeSH
650 _ 2 |a Endothelial Cells: metabolism
|2 MeSH
650 _ 2 |a Endothelial Cells: physiology
|2 MeSH
650 _ 2 |a Receptor, TIE-2: metabolism
|2 MeSH
650 _ 2 |a Receptor, TIE-2: genetics
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Signal Transduction: physiology
|2 MeSH
650 _ 2 |a Signal Transduction: genetics
|2 MeSH
650 _ 2 |a Stroke: genetics
|2 MeSH
650 _ 2 |a Stroke: metabolism
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Blood-Brain Barrier: metabolism
|2 MeSH
650 _ 2 |a Mice, Knockout
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Cerebral Small Vessel Diseases: genetics
|2 MeSH
650 _ 2 |a Cerebral Small Vessel Diseases: metabolism
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
700 1 _ |a González-Gallego, Judit
|b 1
700 1 _ |a Müller, Stephan A
|0 P:(DE-2719)2810938
|b 2
700 1 _ |a Todorov, Mihail Ivilinov
|0 0000-0002-8627-1260
|b 3
700 1 _ |a Seker, Fatma Burcu
|b 4
700 1 _ |a Frerich, Simon
|0 0000-0002-8275-6113
|b 5
700 1 _ |a Cernilogar, Filippo M
|0 0000-0003-2814-3436
|b 6
700 1 _ |a Schröger, Luise
|0 0000-0002-6213-4202
|b 7
700 1 _ |a Malik, Rainer
|b 8
700 1 _ |a Cao, Jiayu
|0 0000-0002-8826-2595
|b 9
700 1 _ |a Llovera, Gemma
|b 10
700 1 _ |a Roth, Stefan
|0 0000-0001-6823-2981
|b 11
700 1 _ |a Schillinger, Ulrike
|b 12
700 1 _ |a Schifferer, Martina
|0 P:(DE-2719)2812260
|b 13
700 1 _ |a Reyahi, Azadeh
|b 14
700 1 _ |a Crusius, Dennis
|b 15
700 1 _ |a Pedro, Liliana D
|b 16
700 1 _ |a Simons, Mikael
|0 P:(DE-2719)2811642
|b 17
700 1 _ |a Carlsson, Peter
|b 18
700 1 _ |a Ertürk, Ali
|b 19
700 1 _ |a Liesz, Arthur
|0 0000-0002-9069-2594
|b 20
700 1 _ |a Schotta, Gunnar
|0 0000-0003-4940-6135
|b 21
700 1 _ |a Plesnila, Nikolaus
|0 P:(DE-2719)9000853
|b 22
700 1 _ |a Lichtenthaler, Stefan F
|0 P:(DE-2719)2181459
|b 23
|u dzne
700 1 _ |a Paquet, Dominik
|0 P:(DE-2719)2010112
|b 24
700 1 _ |a Dichgans, Martin
|0 P:(DE-2719)2000030
|b 25
|e Last author
773 _ _ |a 10.1038/s41593-025-02136-5
|g Vol. 29, no. 2, p. 325 - 336
|0 PERI:(DE-600)1494955-6
|n 2
|p 325 - 336
|t Nature neuroscience
|v 29
|y 2026
|x 1097-6256
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/285050/files/DZNE-2026-00174.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/285050/files/DZNE-2026-00174.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:285050
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810938
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2812260
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2811642
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)2181459
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)2000030
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 2
914 1 _ |y 2026
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT NEUROSCI : 2022
|d 2025-11-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-07
915 _ _ |a DEAL Nature
|0 StatID:(DE-HGF)3003
|2 StatID
|d 2025-11-07
|w ger
915 _ _ |a IF >= 25
|0 StatID:(DE-HGF)9925
|2 StatID
|b NAT NEUROSCI : 2022
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-07
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-07
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2025-11-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-07
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-07
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 0
920 1 _ |0 I:(DE-2719)1110006
|k AG Lichtenthaler
|l Neuroproteomics
|x 1
920 1 _ |0 I:(DE-2719)1110000-4
|k AG Misgeld
|l Neuronal Cell Biology
|x 2
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)1110006
980 _ _ |a I:(DE-2719)1110000-4
980 _ _ |a I:(DE-2719)1110008
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21